Next generation human microbiome therapeutics.
The human microbiome has emerged as a key driver of immune dysfunction. At Siolta Therapeutics, we leverage multi-scale next-generation microbiome analyses to develop and test microbial-based therapeutics for induction and maintenance of immune tolerance.
Microbial seeds for human microbiome management.
At Siolta Therapeutics, we harness information from human microbiome studies to design next-generation microbial therapeutics that re-engineer the human microbiome to prevent or reduce inflammatory processes.
“Understanding and leveraging the microbiome to influence human health, represents one of the most exciting areas of therapeutic development in the modern era.”Susan Lynch – Founder | Board Member
Our research focuses on microbial communities associated with chronic inflammatory diseases of the gastrointestinal and respiratory tracts. Using clinical samples to inform studies using murine models, we examine relationships between microbial community composition and function in an effort to better understand microbial-host interplay in the context of chronic inflammatory disease.
Join Siolta on November 3rd at the 5th Microbiome R&D and Business Collaboration Forum: USA http://www.global-engage.com/event/microbiome/ (2:20pm Dockside)Read More
Thanks to California Life Science Institute (CLSI) for choosing Siolta Therapeutics to participate in the Fall 2017 Fellows All-Star Team (FAST) Advisory Program. California Life Sciences Institute (CLSI) maintains California’s leadership in life sciences innovation through support of entrepreneurship, education and career development.Read More
Translating the Microbiome From the Bench to Bedside: Challenges and Opportunities in Developing bioTherapeutics and Diagnostics - April 12-13th, Boston, MA The Colonnade Hotel
Founder and Vice President, Dr. Nikole Kimes, will be presenting Next Generation Microbial Therapeutics: Challenges in Transforming the Therapeutic Landscape for Atopy and AsthmaRead More
Come hear more about Siolta Therapeutics at the Precision Medicine World Conference 2017 in Palo Alto Jauary 24thRead More
Check out this great microbiome review by Founder, Dr. Susan Lynch, and her colleague, Dr. Oluf Pedersen, in the New England Journal of MedicineRead More